Literature DB >> 30210224

Annual cost of illness of stomach and esophageal cancer patients in urban and rural areas in China: A multi-center study.

Zhixun Yang1, Hongmei Zeng1, Ruyi Xia2, Qian Liu2, Kexin Sun1, Rongshou Zheng1, Siwei Zhang1, Changfa Xia1, He Li1, Shuzheng Liu3, Zhiyi Zhang4, Yuqin Liu5, Guizhou Guo6, Guohui Song7, Yigong Zhu8, Xianghong Wu9, Bingbing Song10, Xianzhen Liao11, Yanfang Chen12, Wenqiang Wei1, Guihua Zhuang2, Wanqing Chen1.   

Abstract

OBJECTIVE: Stomach and esophageal cancer are imposing huge threats to the health of Chinese people whereas there were few studies on the financial burden of the two cancers.
METHODS: Costs per hospitalization of all patients with stomach or esophageal cancer discharged between September 2015 and August 2016 in seven cities/counties in China were collected, together with their demographic information and clinical details. Former patients in the same hospitals were sampled to collect information on annual direct non-medical cost, indirect costs and annual number of hospitalization. Annual direct medical cost was obtained by multiplying cost per hospitalization by annual number of hospitalization. Annual cost of illness (ACI) was obtained by adding the average value of annual direct medical cost, direct non-medical cost and indirect cost, stratified by sex, age, clinical stage, therapy and pathologic type in urban and rural areas. Costs per hospitalization were itemized into eight parts to calculate the proportion of each part. All costs were converted to 2016 US dollars (1 USD=6.6423 RMB).
RESULTS: Totally 19,986 cases were included, predominately male. Mean ages of stomach cancer and urban patients were lower than that of esophageal cancer and rural patients. ACI of stomach and esophageal cancer patients were $10,449 and $13,029 in urban areas, and $2,927 and $3,504 in rural areas, respectively. Greater ACI was associated with male, non-elderly patients as well as those who were in stage I and underwent surgeries. Western medicine fee took the largest proportion of cost per hospitalization.
CONCLUSIONS: The ACI of stomach and esophageal cancer was tremendous and varied substantially among the population in China. Preferential policies of medical insurance should be designed to tackle with this burden and further reduce the health care inequalities.

Entities:  

Keywords:  China; Cost of illness; esophageal neoplasms; stomach neoplasms

Year:  2018        PMID: 30210224      PMCID: PMC6129568          DOI: 10.21147/j.issn.1000-9604.2018.04.07

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  40 in total

1.  Healthcare resource use and medical costs for the management of oesophageal cancer.

Authors:  L G Gordon; S Eckermann; N G Hirst; D I Watson; G C Mayne; P Fahey; D C Whiteman
Journal:  Br J Surg       Date:  2011-11       Impact factor: 6.939

2.  Hospital costs of complications after esophagectomy for cancer.

Authors:  L Goense; W A van Dijk; J A Govaert; P S N van Rossum; J P Ruurda; R van Hillegersberg
Journal:  Eur J Surg Oncol       Date:  2016-12-05       Impact factor: 4.424

3.  Surgery of gastric cancer and esophageal cancer: Does age matter?

Authors:  Henrik Nienhueser; Romy Kunzmann; Leila Sisic; Susanne Blank; Moritz J Strowitzk; Thomas Bruckner; Dirk Jäger; Wilko Weichert; Alexis Ulrich; Markus W Büchler; Katja Ott; Thomas Schmidt
Journal:  J Surg Oncol       Date:  2015-08-25       Impact factor: 3.454

4.  Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.

Authors:  Zhiyuan Zheng; K Robin Yabroff; Gery P Guy; Xuesong Han; Chunyu Li; Matthew P Banegas; Donatus U Ekwueme; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2015-12-24       Impact factor: 13.506

5.  Screening esophagus during routine ultrasound: medical and cost benefits.

Authors:  Abd Elrazek M A Abd Elrazek; Khaled A Eid; Abd Elhalim A El-Sherif; Usama M Abd El Al; Samir M El-Sherbiny; Shymaa E Bilasy
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-01       Impact factor: 2.566

6.  Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study.

Authors:  Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Kelvin Chan; Stuart Peacock; Murray D Krahn
Journal:  CMAJ Open       Date:  2013-01-16

7.  Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric Adenocarcinoma.

Authors:  Luke V Selby; Renee L Gennarelli; Geoffrey C Schnorr; Stephen B Solomon; Mark A Schattner; Elena B Elkin; Peter B Bach; Vivian E Strong
Journal:  JAMA Surg       Date:  2017-10-01       Impact factor: 14.766

8.  Cost of illness of the stomach cancer in Japan - a time trend and future projections.

Authors:  Kayoko Haga; Kunichika Matsumoto; Takefumi Kitazawa; Kanako Seto; Shigeru Fujita; Tomonori Hasegawa
Journal:  BMC Health Serv Res       Date:  2013-07-23       Impact factor: 2.655

9.  Cost-benefit analysis of screening for esophageal and gastric cardiac cancer.

Authors:  Wen-Qiang Wei; Chun-Xia Yang; Si-Han Lu; Juan Yang; Bian-Yun Li; Shi-Yong Lian; You-Lin Qiao
Journal:  Chin J Cancer       Date:  2011-03

10.  Cost comparison between surgical treatments and endoscopic submucosal dissection in patients with early gastric cancer in Korea.

Authors:  Younhee Kim; Young Woo Kim; Il Ju Choi; Joo Young Cho; Jong Hee Kim; Jin Won Kwon; Ja Youn Lee; Na Rae Lee; Sang Yong Seol
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

View more
  18 in total

1.  Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.

Authors:  Shuxia Qin; Xuehong Wang; Sini Li; Chongqing Tan; Xiaohui Zeng; Xia Luo; Lidan Yi; Liubao Peng; Meiyu Wu; Ye Peng; Liting Wang; Xiaomin Wan
Journal:  Pharmacoeconomics       Date:  2022-06-15       Impact factor: 4.558

2.  Secular Trend of Cancer Death and Incidence in 29 Cancer Groups in China, 1990-2017: A Joinpoint and Age-Period-Cohort Analysis.

Authors:  Xiaoxue Liu; Maigeng Zhou; Fang Wang; Sumaira Mubarik; Yafeng Wang; Runtang Meng; Fang Shi; Haoyu Wen; Chuanhua Yu
Journal:  Cancer Manag Res       Date:  2020-07-23       Impact factor: 3.989

3.  The miRNA, miR-125b, Inhibited Invasion and Metastasis of Gastric-Cancer Cells by Triggering the STAT3 Signaling Pathway.

Authors:  Xiangqian Xu; Zhongqin Dang; Junping Zhang; Yingpu Feng; Zheng Wei
Journal:  Cancer Manag Res       Date:  2020-09-17       Impact factor: 3.989

4.  Pyk2 level is a novel prognostic marker for patients with esophageal squamous cell carcinoma after radical surgery.

Authors:  Tong Zhu; Qiuxing Yang; Jingjing Shao; Zhuolin Chen; Bo Cai; Guoxin Mao
Journal:  Virchows Arch       Date:  2021-07-27       Impact factor: 4.064

5.  FAT1, a direct transcriptional target of E2F1, suppresses cell proliferation, migration and invasion in esophageal squamous cell carcinoma.

Authors:  Yu Wang; Guangchao Wang; Yunping Ma; Jinglei Teng; Yan Wang; Yongping Cui; Yan Dong; Shujuan Shao; Qimin Zhan; Xuefeng Liu
Journal:  Chin J Cancer Res       Date:  2019-08       Impact factor: 5.087

6.  The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.

Authors:  Kai Zhou; Anqiang Wang; Sheng Ao; Jiahui Chen; Ke Ji; Qifei He; Xin Ji; Xiaojiang Wu; Ji Zhang; Zhongwu Li; Zhaode Bu; Jiafu Ji
Journal:  BMC Cancer       Date:  2020-07-17       Impact factor: 4.430

7.  A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.

Authors:  Yong Tang; Zhu'an Ou; Zhifang Yao; Guibin Qiao
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

8.  A decision analysis comparing three strategies for peritoneal lavage cytology testing in staging of gastric cancer in China.

Authors:  Qifei He; Jinyi Zhu; Anqiang Wang; Ke Ji; Xin Ji; Ji Zhang; Xiaojiang Wu; Xia Li; Zhaode Bu; Jiafu Ji
Journal:  Cancer Med       Date:  2020-10-13       Impact factor: 4.452

9.  Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma.

Authors:  Bo Zhang; Xi Wang; Qun Li; Hongnan Mo; Xingyuan Wang; Yan Song; Jianping Xu; Tao Qu; Jing Huang
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

10.  Expenditure and Financial Burden for Stomach Cancer Diagnosis and Treatment in China: A Multicenter Study.

Authors:  Kai Zhang; Jian Yin; Huiyao Huang; Le Wang; Lanwei Guo; Jufang Shi; Min Dai
Journal:  Front Public Health       Date:  2020-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.